MCID: PNC008
MIFTS: 37

Pancreatic Endocrine Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Pancreatic Endocrine Carcinoma

MalaCards integrated aliases for Pancreatic Endocrine Carcinoma:

Name: Pancreatic Endocrine Carcinoma 12 15 73
Malignant Neoplasm of Islets of Langerhans 12
Pancreatic Neuroendocrine Carcinoma 12
Carcinoma of Endocrine Pancreas 12
Carcinoma, Islet Cell 44
Islet Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1798
ICD10 33 C25.4
ICD9CM 35 157.4
MeSH 44 D018273
NCIt 50 C3770
UMLS 73 C1328479

Summaries for Pancreatic Endocrine Carcinoma

Disease Ontology : 12 An islet cell tumor that has material basis in epithelial cells.

MalaCards based summary : Pancreatic Endocrine Carcinoma, also known as malignant neoplasm of islets of langerhans, is related to somatostatinoma and islet cell tumor. An important gene associated with Pancreatic Endocrine Carcinoma is MEG3 (Maternally Expressed 3
We found that Meg3 has tumor-suppressor activity in PNET cells because the overexpression of Meg3 in MIN6 cells (insulin-secreting mouse PNET cell line) blocked cell proliferation and delayed cell cycle progression. Gene expression microarray analysis showed that Meg3 overexpression in MIN6 mouse insulinoma cells down-regulated the expression of the protooncogene c-Met (hepatocyte growth factor receptor),and these cells showed significantly reduced cell migration/invasion. Compared with normal islets,mouse or human MEN1-associated PNETs expressed less MEG3 and more c-MET
Dysfunction Pattern: Regulation [down-regulated]), and among its related pathways/superpathways is Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Oxaliplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and endothelial.

Related Diseases for Pancreatic Endocrine Carcinoma

Diseases related to Pancreatic Endocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Related Disease Score Top Affiliating Genes
1 somatostatinoma 11.5
2 islet cell tumor 11.1
3 neuroendocrine carcinoma of pancreas 11.1
4 esophageal neuroendocrine tumor 10.4 NCAM1 SYP
5 ovarian large-cell neuroendocrine carcinoma 10.4 NCAM1 SYP
6 lung combined type small cell carcinoma 10.4 NCAM1 SYP
7 carcinoid tumors, intestinal 10.4 SSTR2 SYP
8 sensory organ benign neoplasm 10.4 NCAM1 SYP
9 gallbladder small cell carcinoma 10.4 NCAM1 SYP
10 cutaneous ganglioneuroma 10.4 NCAM1 SYP
11 extrahepatic bile duct adenocarcinoma 10.4 NCAM1 SYP
12 orbital cancer 10.4 NCAM1 SYP
13 hypoganglionosis 10.4 NCAM1 SYP
14 olfactory neuroblastoma 10.4 SSTR2 SYP
15 pancreatic serous cystadenoma 10.4 NCAM1 SYP
16 conventional angiosarcoma 10.4 NCAM1 SYP
17 supratentorial primitive neuroectodermal tumor 10.4 NCAM1 SYP
18 endometrial small cell carcinoma 10.4 NCAM1 SYP
19 mediastinal cancer 10.4 NCAM1 SYP
20 hormone producing pituitary cancer 10.4 SSTR2 SSTR5
21 angiomyoma 10.3 NCAM1 SYP
22 gastric squamous cell carcinoma 10.3 NCAM1 SYP
23 gastric small cell carcinoma 10.3 NCAM1 SYP
24 subependymoma 10.3 NCAM1 SYP
25 pancreatitis 10.3
26 cervical clear cell adenocarcinoma 10.3 NCAM1 SYP
27 spermatocele 10.3 NCAM1 SYP
28 cervix small cell carcinoma 10.3 NCAM1 SYP
29 large cell neuroendocrine carcinoma 10.3 NCAM1 SYP
30 adrenal rest tumor 10.3 NCAM1 SYP
31 ganglioneuroma 10.2 NCAM1 SYP
32 lung benign neoplasm 10.2 NCAM1 SYP
33 pituitary carcinoma 10.2 MEG3 SSTR2
34 small cell carcinoma 10.2 NCAM1 SYP
35 peripheral nervous system neoplasm 10.2 NCAM1 SYP
36 autonomic nervous system neoplasm 10.2 NCAM1 SYP
37 large cell carcinoma 10.2 NCAM1 SYP
38 pituitary adenoma, prolactin-secreting 10.1 SSTR2 SSTR5
39 merkel cell carcinoma 10.0 NCAM1 SYP
40 cell type benign neoplasm 10.0 SSTR5 SYP
41 mixed ductal-endocrine carcinoma 10.0 NCAM1 SSTR2 SYP
42 neuroendocrine tumor 10.0 NCAM1 SSTR2 SYP
43 acromegaly 9.9 SSTR2 SSTR5
44 diabetes mellitus 9.7
45 hepatitis 9.7
46 adenocarcinoma 9.7
47 cholangitis 9.7
48 hirschsprung disease 1 9.7 MEG3 NCAM1 SYP
49 medulloblastoma 9.5 NCAM1 SSTR2 SYP
50 thyroid carcinoma, familial medullary 9.5 SSTR2 SSTR5

Graphical network of the top 20 diseases related to Pancreatic Endocrine Carcinoma:



Diseases related to Pancreatic Endocrine Carcinoma

Symptoms & Phenotypes for Pancreatic Endocrine Carcinoma

Drugs & Therapeutics for Pancreatic Endocrine Carcinoma

Drugs for Pancreatic Endocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Somatostatin Approved, Investigational Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
7
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
9 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1,Not Applicable
11 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1,Not Applicable
12 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
13 Antimetabolites Phase 2, Phase 3,Phase 1
14 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
15 Analgesics Phase 3
16 Central Nervous System Depressants Phase 3
17 Adjuvants, Anesthesia Phase 3
18 Narcotics Phase 3
19 Analgesics, Opioid Phase 3
20 Anesthetics Phase 3
21 Hormone Antagonists Phase 2, Phase 3,Phase 1
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Hormones Phase 2, Phase 3,Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
26 Peripheral Nervous System Agents Phase 3
27 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
28 Folate Nutraceutical Phase 2, Phase 3
29 Vitamin B9 Nutraceutical Phase 2, Phase 3
30 Cola Nutraceutical Phase 3,Phase 2,Phase 1
31
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
32
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
33
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
34
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
35
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
36
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
37
Sunitinib Approved, Investigational Phase 2,Not Applicable 341031-54-7, 557795-19-4 5329102
38
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
39
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
40
Melphalan Approved Phase 2 148-82-3 4053 460612
41
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
42
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
43
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
44
Pancrelipase Approved, Investigational Phase 2 53608-75-6
45
Etoposide Approved Phase 2 33419-42-0 36462
46
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
47
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
48
nivolumab Approved Phase 2 946414-94-4
49
Lenograstim Approved, Investigational Phase 2 135968-09-1
50
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer Completed NCT00781911 Phase 2 depot octreotide
5 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
6 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
7 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
8 RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
9 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT02101918 Phase 2
10 Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed NCT01169649 Phase 2 MK-2206
11 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
12 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
13 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
14 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
15 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
16 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
17 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
18 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
19 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
20 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
21 Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II Recruiting NCT02230176 Phase 2 Sunitinib;177Lu-DOTA0-Tyr3-Octreotate
22 Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer Recruiting NCT02820857 Phase 2 Folfiri-bevacizumab;Folfiri
23 Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery Recruiting NCT02595424 Phase 2 Capecitabine;Carboplatin;Cisplatin;Etoposide;Temozolomide
24 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Recruiting NCT02893930 Phase 2 Sapanisertib
25 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Recruiting NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride
26 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
27 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
28 FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Active, not recruiting NCT03042780 Phase 2 FOLFIRINOX;Granulocyte colony-stimulating factor (G-CSF)
29 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
30 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
31 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
32 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
33 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
34 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
35 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
36 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
37 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
38 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
39 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
40 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
41 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
42 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
43 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
44 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
45 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
46 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
47 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
48 Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene Completed NCT00444795 Sunitinib malate;Sunitinib malate;sunitinib malate
49 A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Completed NCT00428220 Not Applicable sunitinib
50 Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders Recruiting NCT00830557

Search NIH Clinical Center for Pancreatic Endocrine Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoma, islet cell

Genetic Tests for Pancreatic Endocrine Carcinoma

Anatomical Context for Pancreatic Endocrine Carcinoma

MalaCards organs/tissues related to Pancreatic Endocrine Carcinoma:

41
Pancreas, Liver, Endothelial, Kidney, Bone

Publications for Pancreatic Endocrine Carcinoma

Articles related to Pancreatic Endocrine Carcinoma:

(show all 17)
# Title Authors Year
1
Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. ( 27160433 )
2016
2
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. ( 21831734 )
2011
3
Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. ( 21868544 )
2011
4
Pancreatic endocrine carcinoma protruding from the major papilla. ( 20144741 )
2010
5
A case of multiple hepatic metastases from pancreatic endocrine carcinoma. ( 18573853 )
2008
6
Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. ( 18362846 )
2008
7
Successful pancreatectomy with en-bloc resection of the celiac artery and portal vein for pancreatic endocrine carcinoma. ( 17629086 )
2007
8
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. ( 16364959 )
2006
9
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. ( 17158766 )
2006
10
Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. ( 15920550 )
2005
11
Somatostatin-producing pancreatic endocrine carcinoma presented as relapsing cholangitis -- a case report. ( 15849491 )
2005
12
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? ( 14962717 )
2004
13
Curative resection for a pancreatic endocrine carcinoma involving the portal vein. ( 15532841 )
2004
14
Dpc4 is expressed in virtually all primary and metastatic pancreatic endocrine carcinomas. ( 11964045 )
2002
15
Pancreatic endocrine carcinoma with multiple hormone production in a raccoon (Procyon lotor). ( 10213674 )
1999
16
Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. ( 1322859 )
1992
17
Pancreatic endocrine carcinoma with ectopic PTH-production and paraneoplastic hypercalcaemia. ( 3082066 )
1986

Variations for Pancreatic Endocrine Carcinoma

Expression for Pancreatic Endocrine Carcinoma

Search GEO for disease gene expression data for Pancreatic Endocrine Carcinoma.

Pathways for Pancreatic Endocrine Carcinoma

Pathways related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.52 NCAM1 SYP

GO Terms for Pancreatic Endocrine Carcinoma

Cellular components related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.8 SSTR2 SSTR5 SYP

Biological processes related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.26 SSTR2 SSTR5
2 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.16 SSTR2 SSTR5
3 cellular response to glucocorticoid stimulus GO:0071385 8.96 SSTR2 SSTR5
4 somatostatin signaling pathway GO:0038170 8.62 SSTR2 SSTR5

Molecular functions related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.16 SSTR2 SSTR5
2 neuropeptide binding GO:0042923 8.96 SSTR2 SSTR5
3 somatostatin receptor activity GO:0004994 8.62 SSTR2 SSTR5

Sources for Pancreatic Endocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....